0 CHECKOUT

Smallpox - Pipeline Review, H2 2015

  • ID: 3429788
  • August 2015
  • 86 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • CEL-SCI Corporation
  • Chimerix, Inc.
  • EpiVax, Inc.
  • Nanotherapeutics, Inc.
  • Oncovir, Inc.
  • MORE

Smallpox - Pipeline Review, H2 2015

Summary

The report ‘Smallpox - Pipeline Review, H2 2015’, provides an overview of the Smallpox’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bavarian Nordic A/S
  • CEL-SCI Corporation
  • Chimerix, Inc.
  • EpiVax, Inc.
  • Nanotherapeutics, Inc.
  • Oncovir, Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Smallpox Overview

Therapeutics Development

Pipeline Products for Smallpox - Overview

Pipeline Products for Smallpox - Comparative Analysis

Smallpox - Therapeutics under Development by Companies

Smallpox - Therapeutics under Investigation by Universities/Institutes

Smallpox - Pipeline Products Glance

Late Stage Products

Early Stage Products

Unknown Stage Products

Smallpox - Products under Development by Companies

Smallpox - Products under Investigation by Universities/Institutes

Smallpox - Companies Involved in Therapeutics Development

Bavarian Nordic A/S

CEL-SCI Corporation

Chimerix, Inc.

EpiVax, Inc.

Nanotherapeutics, Inc.

Oncovir, Inc.

SIGA Technologies, Inc.

Symphogen A/S

TapImmune Inc.

Tonix Pharmaceuticals Holding Corp.

Smallpox - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

24a - Drug Profile

Product Description

Mechanism of Action

R&D Progress

brincidofovir - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cidofovir - Drug Profile

Product Description

Mechanism of Action

R&D Progress

imatinib mesylate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Infectious Disease - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PL-801 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Poly-ICLC - Drug Profile

Product Description

Mechanism of Action

R&D Progress

small pox vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

smallpox vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

smallpox vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Sym-002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tecovirimat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TPIV-300 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VIR-002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Smallpox - Recent Pipeline Updates

Smallpox - Dormant Projects

Smallpox - Discontinued Products

Smallpox - Product Development Milestones

Featured News & Press Releases

Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox

Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million

May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine

Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery

Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million

Dec 23, 2014: Chimerix Provides Recap of 2014 Events

Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine

Sep 04, 2014: Bavarian Nordic Announces Exercise Of Contract Option By The U.S. Government For Continued Supply Of Imvamune Smallpox Vaccine

Sep 02, 2014: Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox

Aug 26, 2014: Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE Smallpox Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Smallpox, H2 2015

Number of Products under Development for Smallpox - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Smallpox - Pipeline by Bavarian Nordic A/S, H2 2015

Smallpox - Pipeline by CEL-SCI Corporation, H2 2015

Smallpox - Pipeline by Chimerix, Inc., H2 2015

Smallpox - Pipeline by EpiVax, Inc., H2 2015

Smallpox - Pipeline by Nanotherapeutics, Inc., H2 2015

Smallpox - Pipeline by Oncovir, Inc., H2 2015

Smallpox - Pipeline by SIGA Technologies, Inc., H2 2015

Smallpox - Pipeline by Symphogen A/S, H2 2015

Smallpox - Pipeline by TapImmune Inc., H2 2015

Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Smallpox Therapeutics - Recent Pipeline Updates, H2 2015

Smallpox - Dormant Projects, H2 2015

Smallpox - Dormant Projects (Contd..1), H2 2015

Smallpox - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Smallpox, H2 2015

Number of Products under Development for Smallpox - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Bavarian Nordic A/S
CEL-SCI Corporation
Chimerix, Inc.
EpiVax, Inc.
Nanotherapeutics, Inc.
Oncovir, Inc.
SIGA Technologies, Inc.
Symphogen A/S
TapImmune Inc.
Tonix Pharmaceuticals Holding Corp.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Cache

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.